On Mounjaro, patients lose weight faster than on Ozempic: Study

Shares of Novo Nordisk (NVO) are falling after a new study found that Eli Lilly's (LLY) GLP-1 weight-loss drug tirzepatide (Mounjaro) leads to faster and greater weight loss results than semaglutide (Ozempic). Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the study and how it's affecting Novo Nordisk's stock valuation.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Melanie Riehl

Video Transcript

All right, let's take a look at shares of Novo Nordis they are following this morning after a new found after a new study found that Eli Lilly's Manja has seen faster and greater weight loss results here at the takeaways.

Our very own Angeli Kelani and you guys are gonna hate this.

It's such a nuanced report.

It's such a nuanced report.

But yes, the final result is not surprising.

We did already know based on the phase three trials from both these companies that both uh Eli Lily's drugs did have better weight loss results than Novo.

Now, we looked at the, some of the study looked at some time which is NOVO drugs for OIC and we go and zide, which is MJ and Z bound.

And what they found was that over time when adjusted for characteristics of these patients MJ, which was the diabetes drug did a better job of weight loss.

No surprise there.

We saw that during the face, the face three trials.

What is interesting is that in the initial look at the study looked like it was faring better for weight loss.

But then once they adjusted the patients that they were looking at, that's when they found to be better.

This was not a randomized trial.

It did not include a head to head actual study.

This is sort of a retrospective look at patient information from pharmacy.

About 9000 patients were looked at and that's where this information came from.

So while we do already know that the weight loss drugs for about these companies, you know, have a bit of a difference, This kind of puts it in a front light.

We also do know that both companies contend that this was looking at the diabetes drugs and diabetes patients when we know that the higher doses for both drugs actually encourage greater weight loss because there are higher doses of each formula.

So that is really some of the nuance that goes into this.

But of course, we know uh novo slightly under pressure because of this.

You know, I was prepared.

I didn't know if I was gonna be able to follow you through that report, but I think we all on the same page.

Right.

Great stuff.

Thanks so much.